Section Arrow
OMER.NASDAQ
- Omeros Corp
Quotes are at least 15-min delayed:2025/07/20 16:58 EDT
Regular Hours
Last
 3.36
-0.12 (-3.45%)
Day High 
3.63 
Prev. Close
3.48 
1-M High
4.02 
Volume 
681.36K 
Bid
3.35
Ask
3.6
Day Low
3.34 
Open
3.55 
1-M Low
2.95 
Market Cap 
203.90M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.44 
20-SMA 3.33 
50-SMA 3.63 
52-W High 13.6 
52-W Low 2.95 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.65/1.19
Enterprise Value
383.95M
Balance Sheet
Book Value Per Share
-3.64
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed:2025/07/20 16:58 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.